CSPC Innovation pursues Hong Kong IPO as parent profits shrink
The producer of food additives and pharmaceutical ingredients is aiming to raise fresh capital to support its drive to become a developer of innovative drugs Key takeaways: R&D costs have…
Recent Articles
RELATED ARTICLES
-
Big deal, bigger doubts: CSPC slides after $18.5 billion pact
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
- Mega licensing deal lifts 3SBio profits but core sales slip
- Cosmoplat asserts independence from parent Haier with Hong Kong IPO
- China’s biopharma sector enters the New Year on a high
- Jacobio Pharma poised to turn a profit from precision cancer drugs
